Tuesday, December 13, 2011

Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)

Additional Key Nplate Data Also Presented at American Society of Hematology Annual Meeting

THOUSAND OAKS, Calif., Dec. 13, 2011 /PRNewswire/—Amgen (NASDAQ:AMGN) today announced that data from several key Nplate® (romiplostim) studies were presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 10-13, 2011, in San Diego. Of note, final results from the international, Phase 3, open-label, single-arm ‘209 study evaluating the safety and efficacy of Nplate in adults with primary immune thrombocytopenia (ITP) demonstrated that Nplate induced a rapid platelet response in adult ITP patients with low platelet counts or bleeding symptoms and maintained a consistent safety profile (Abstract No. 3279).

Read the rest of this entry

Posted in Press Releases

Friday, December 09, 2011

Amgen to Present at the 22nd Annual Oppenheimer Healthcare Conference

THOUSAND OAKS, Calif., Dec. 9, 2011 /PRNewswire/—Amgen (NASDAQ:AMGN) will participate in the Oppenheimer Healthcare Conference on Wednesday, Dec. 14, 2011, at the Waldorf Astoria Hotel in New York City, beginning at 1:35 p.m.  Eastern Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases

Thursday, December 08, 2011

Amgen Announces Preliminary Results of Its Tender Offer

THOUSAND OAKS, Calif., Dec. 8, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, on Wednesday, Dec. 7, 2011.

Based on the preliminary count by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 98,062,630 shares of Amgen’s common stock were properly tendered and not properly withdrawn at or below the purchase price of $60.00 per share, including 30,827,827 shares that were tendered through notice of guaranteed delivery. Amgen has been informed by the depositary that the preliminary proration factor for the tender offer is approximately 85 percent.

Read the rest of this entry

Posted in Press Releases

Tuesday, December 06, 2011

Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy

Prescribing Physicians, Patients and Institutions no Longer Required to Enroll in Nplate® NEXUS Program

THOUSAND OAKS, Calif., Dec. 6, 2011 /PRNewswire/—Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate® (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program. Prescribing physicians, patients and institutions are no longer required to enroll in the safety monitoring program, called the Nplate® NEXUS (Network of EXperts Understanding and Supporting Nplate and Patients) Program, in order to prescribe or receive Nplate.

Read the rest of this entry

Posted in Press Releases